Effectiveness of WhatsApp Education and Support Messages for Urolithiasis Prevention
Launched by RABIN MEDICAL CENTER · Nov 16, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of WhatsApp to help people who have had kidney stones, also known as urolithiasis, prevent them from coming back. Researchers believe that sending educational messages and support through WhatsApp could help patients follow their doctor's advice better, which may lead to fewer kidney stones in the future. Participants in the study will receive important information about dietary changes and fluid intake that can help reduce the risk of stones, all delivered conveniently through their phones.
To participate, individuals need to be between the ages of 65 and 74, have a history of kidney stones, and own a mobile phone with the WhatsApp app. They should also be comfortable reading messages in Hebrew. The trial is currently recruiting participants, and those involved can expect to receive helpful tips and support over the course of the study, aimed at improving their health and preventing future kidney stones.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Capacity to give informed consent
- • Personal history of urolithiasis
- • Stone free status
- • A personal mobile phone with WhatsApp Messenger® application
- Exclusion Criteria:
- • Children
- • Does not read Hebrew, the language in which the messages are written
About Rabin Medical Center
Rabin Medical Center is a leading healthcare institution located in Israel, renowned for its commitment to advancing medical research and patient care. As a prominent clinical trial sponsor, the center focuses on innovative therapies and cutting-edge treatments across various disciplines, including cardiology, oncology, and neurology. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, Rabin Medical Center is dedicated to fostering scientific excellence and ensuring the safety and well-being of participants. The center's collaborative approach, combined with its state-of-the-art facilities, positions it at the forefront of clinical research, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Petah Tikva, , Israel
Patients applied
Trial Officials
MIchael Frumer, MD
Principal Investigator
Rabin Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials